Before buying critical illness cover: definitions, waiting periods, disclosure and how claims are decided

What critical illness insurance is

Critical illness insurance is long-term insurance that pays a lump sum when the insured, during the policy term, is diagnosed by a registered doctor with a condition that is listed in the policy and meets the definition written in the policy, or undergoes a specified surgery. The money is unrestricted. The Insurance Authority's October 2024 consumer leaflet describes typical entry ages of 15 days to 65 and cover up to whole of life; covered conditions usually include cancer, stroke, heart conditions and serious diseases of major organs, with the exact scope set by each policy.

The decisive words are "meets the definition". Every covered condition carries diagnostic criteria: which specialist must diagnose, which pathology or imaging evidence is required, how long symptoms must persist, which severity grade applies. The Insurance Complaints Bureau's Complaints Panel put it the same way in both its 2024-25 and 2025-26 annual reports: all requirements specified for the listed condition must be satisfied. In one 2024-25 case the insured was diagnosed with neuromyelitis optica spectrum disorder and claimed under "multiple sclerosis"; the Panel found the two are distinct diseases under ICD-10 and upheld the decline of a claim of about HK$780,000. In a 2025-26 case a meningioma removed at a Mainland hospital did not meet the policy's "benign brain tumour" definition, which required a life-threatening tumour in the brain with signs of raised intracranial pressure; a HK$1,200,000 claim was declined and upheld.

Five things decide a payout

Definitions and the 2026 HKFI standard

Definitions differ between insurers. A press comparison of six insurers in August 2024 found stroke definitions requiring neurological deficit lasting at least four weeks at one insurer and six weeks at another, cardiomyopathy thresholds at NYHA class 4 versus class 3, and coronary artery disease requiring two vessels narrowed 60% versus one vessel narrowed 50%.

The Hong Kong Federation of Insurers published its Best Practice on Standardization of Critical Illness Definitions in March 2026, effective 1 September 2026. It standardizes bilingual definitions for 16 major conditions (major cancer, severe heart attack, stroke with permanent neurological deficit, other serious coronary artery disease, end stage kidney failure, open chest heart valve surgery, end stage lung disease, open surgery to aorta, major head trauma, end stage liver failure, severe primary cardiomyopathy, benign brain tumour, major organ transplant, coronary artery bypass surgery, severe Parkinson's disease, dementia with severe cognitive impairment) and 5 minor conditions (percutaneous transluminal coronary angioplasty, carcinoma-in-situ, early stage cancer, endovascular treatment for cerebral aneurysm, severe autism spectrum disorder), plus the term "Activities of Daily Living". The HKFI says these account for about 90% of claims. Participation is voluntary; participating insurers display a Q-mark; the standard is a minimum, applies to new individual products in its first phase, uses whole-day thresholds (30, 60, 90 or 180 days), allows different criteria for second and subsequent claims of the same condition, and will be reviewed every two to three years. Existing, renewed and reinstated policies keep their original wording; insurers may not substitute the new definitions unilaterally.

Early-stage and multiple-claim benefits

Early-stage conditions are paid as an advance of a percentage of the sum insured, commonly 20% to 35% in published product documents, and deducted from total cover; carcinoma-in-situ and angioplasty are often claimable twice. Multiple-claim products start after total payments reach 100% of the sum insured and count by condition group (cancer; heart attack and stroke; others) with claim caps, an interval between claims (commonly one to two years) and a total multiple (published examples 300% to 700% of the sum insured). Subsequent cancer claims usually require a new cancer, or a recurrence, spread or continuation of the earlier cancer with "active treatment" (surgery, radiotherapy, chemotherapy, targeted or immunotherapy, not palliative or hormonal treatment) in the preceding period. Complications of a condition already paid are generally excluded.

Waiting, survival and cooling-off periods

The waiting period runs from the policy effective date (or reinstatement date) and excludes conditions whose signs, symptoms or diagnosis arise within it; published term products commonly use 90 days, with conditions directly caused by an accident and diagnosed within the same period exempt. The Insurance Authority notes that some conditions, such as psychiatric or autoimmune diseases, may carry longer waiting periods, up to a year. The survival period runs from diagnosis or surgery and commonly requires 14 to 30 days; its purpose is to avoid overlap with death benefit. The cooling-off period under IA Guideline GL29 is 21 calendar days, during which the policy can be cancelled for a refund of premium.

Underwriting and the duty of disclosure

Hong Kong insurance contracts rest on utmost good faith: the applicant must disclose material facts, including those a reasonable person would be expected to know, and material non-disclosure allows the insurer to avoid the policy. The Complaints Panel asks whether the undisclosed fact (1) would influence a prudent underwriter, (2) was known to the applicant and (3) could reasonably be expected to be disclosed; if so it generally supports the insurer even where the fact is unrelated to the illness claimed. In a 2024-25 case, thyroid nodules found at a check-up a year before application, with advice to have a biopsy and follow-up, were not disclosed; a breast cancer claim of about HK$530,000 was declined and upheld. In another, an applicant who re-declared on the issue date that a liver record belonged to her father was awarded HK$1,200,000. Underwriting outcomes are standard rates, loading, exclusion, postponement or decline, and vary by insurer.

Premiums, levy and tax

Term critical illness cover is pure protection with premiums stepping up by age band; published product documents state that standard premium rates are not guaranteed and may change with claims and renewal experience. Whole-life cover fixes premiums over a payment term and builds guaranteed cash value at a higher cost; savings-type structures attach critical illness cover to participating policies whose cash value includes non-guaranteed bonuses. The Insurance Authority levy is 0.1% of premium, capped at HK$100 per life policy per policy year since 1 April 2021. Critical illness premiums are not tax-deductible in Hong Kong; only VHIS premiums (HK$8,000 per insured person per year) and qualifying deferred annuity premiums or tax-deductible MPF voluntary contributions (HK$60,000 combined) are.

Claims and disputes

A claim requires the insurer's claim form, the attending physician's statement, pathology, imaging and laboratory reports, discharge summaries and a medical records authorization; insurers verify with doctors and hospitals and review pre-application records. One insurer's April 2026 claims report cites an average processing time of 5 days and a 93% critical illness claim success rate, with cancer accounting for 73% of its critical illness claims. In 2025 the Insurance Complaints Bureau received 857 new complaints and closed 447 claim-related cases; of 75 critical illness cases, 52 concerned application of policy terms and 19 non-disclosure. Complaints must be lodged within six months of the insurer's final decision; the Bureau's jurisdiction limit has been HK$1.5 million since 1 January 2025; 124 complainants received about HK$13.6 million in 2025.

Mainland residents

Mainland residents must complete the entire sales process and sign all application documents in Hong Kong, deal directly with a Hong Kong licensed intermediary, and sign the Important Facts Statement for Mainland Policyholders (IFS-MP, applicable since 1 September 2016), which covers sales location, non-guaranteed returns, surrender losses, exchange-rate and policy risks, prohibition of rebates, source-of-funds verification and the possibility of attending in Hong Kong for complaints or litigation. Hong Kong has no statutory two-year incontestability rule comparable to Mainland insurance law, so the duty of disclosure is more enduring. Mainland regulators have issued risk warnings on buying Hong Kong policies; readers should obtain advice in their own jurisdiction. This site carries on no sales activity in Mainland China.

Why it matters: Hong Kong numbers

The Hong Kong Cancer Registry recorded 37,953 new cancer cases in 2023, about 104 a day; lung, breast, colorectal, prostate and liver cancers made up 58%; roughly one in four men and one in five women develop cancer before age 75; the median age at diagnosis is 67; five-year relative survival for patients aged 15 and over rose from 49.1% (2010-2013) to 55.7% (2018-2022). Longer survival means longer treatment and recovery, which is the expense a critical illness lump sum is designed to cover.